Qube Research & Technologies LTD Tcr2 Therapeutics Inc. Transaction History

Qube Research & Technologies LTD

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$1.86 - $3.75 $5,113 - $10,308	-2,749 Reduced 10.5%	23,431 $42,000
Q2 2022 Aug 15, 2022	BUY	$2.11 - $2.94 $55,239 - $76,969	26,180 New	26,180 $76,000
Q4 2021 Feb 01, 2022	SELL	$4.58 - $8.34 $173,055 - $315,126	-37,785 Closed	0 $0
Q3 2021 Nov 12, 2021	SELL	$8.44 - $18.35 $247,671 - $538,480	-29,345 Reduced 43.71%	37,785 $322,000
Q2 2021 Aug 13, 2021	BUY	$16.41 - $24.71 $649,704 - $978,318	39,592 Added 143.77%	67,130 $1.1 Million
Q1 2021 May 14, 2021	BUY	$20.38 - $34.07 $561,224 - $938,219	27,538 New	27,538 $608,000

Ticker TCRR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 38,606,400
Description
TCR2 Therapeutics Inc., a clinical-stage immunotherapy company, focuses on developing novel T cell receptor (TCR) therapies for patients suffering from cancer. The company's lead product candidates include gavo-cel, a mono TCR Fusion Construct T cells (TRuC-T cells) targeting mesothelin positive solid tumors, which is in phase I/II clinical tria...

Get notified when there are updates to the investment portfolio of Qube Research & Technologies LTD, based on Form 13F filings with the SEC.

Stay updated on Qube Research & Technologies LTD with notifications on news.